Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

      Evolent Health Logo (PRNewsfoto/Evolent Health)

      News provided by

      Evolent Health, Inc.

      Feb 24, 2026, 16:10 ET

      Share this article

      Share this article


      WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025.

      Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximately 30% for 2026 demonstrates the power and durability of Evolent's specialty model. While the addition of $900 million in new Performance Suite revenue in 2026, as well as the impact of significant health plan customer membership decreases in their Exchange products, create an impact on Adjusted EBITDA in the first half of the year, we believe our year-end 2026 margins should quickly step-up as new contract reserving effects ease throughout the year and our operating cost reduction plan ramps up across 2026.  Most importantly, we believe we will continue to see a sizable market opportunity as health plans turn to Evolent for help in balancing quality and affordability for their members as they navigate oncology, cardiology, and musculoskeletal conditions."

      Highlights for the three months and year ended December 31, 2025 include (dollars in thousands, except for average PMPM fees and revenue per case):


      For the Three Months
      Ended December 31, 2025


      For the Year Ended
      December 31, 2025

      Financial Results:




      Revenue

      $                           468,719


      $                           1,876,229

      Net loss attributable to common shareholders of Evolent Health, Inc.

      $                          (429,131)


      $                             (579,401)

      Net loss margin

      (91.6) %


      (30.9) %

      Adjusted EBITDA

      $                             37,793


      $                              151,155

      Adjusted EBITDA Margin

      8.1 %


      8.1 %





      Average Lives on Platform/Cases




      Performance Suite

      6,475


      6,482

      Specialty Technology and Services Suite

      79,677


      77,983

      Administrative Services

      1,218


      1,221

      Cases

      14


      53





      Average Unique Members

      40,038


      40,425





      Average PMPM Fees/ Revenue per Case




      Performance Suite

      $                               13.87


      $                                  14.48

      Specialty Technology and Services Suite

      0.40


      0.38

      Administrative Services

      15.27


      15.47

      Cases

      3,537


      3,168





      Medical Expense Ratio

      90.2 %


      80.5 %

      Medical Expense Ratio excluding Evolent Care Partners

      94.8 %


      89.0 %

      The rising medical costs impacting health plans continue to drive robust demand for Evolent's complex specialty care solutions.

      Financial Results of Evolent Health, Inc.

      In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss  financial measures not prepared in accordance with generally accepted accounting principles ("GAAP"). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See Non-GAAP Financial Measures for more information.

      Reported Results

      Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):


      For the Three Months Ended
      December 31,


      For the Year Ended
      December 31,


      2025


      2024


      2025


      2024

      Revenue

      $      468,719


      $   646,542


      $ 1,876,229


      $   2,554,741

      Cost of revenue

      $      371,466


      $   570,831


      $ 1,476,346


      $   2,187,388

      Selling, general and administrative expenses

      $        72,656


      $     47,701


      $    303,866


      $      263,050

      Net loss attributable to common shareholders of Evolent Health, Inc.

      $     (429,131)


      $    (30,615)


      $   (579,401)


      $       (93,454)

      Net loss margin

      (91.6) %


      (4.7) %


      (30.9) %


      (3.7) %

      Loss per share attributable to common shareholders of Evolent Health, Inc.








      Basic and diluted

      $           (3.84)


      $        (0.27)


      $         (5.07)


      $           (0.81)

      Total cash and cash equivalents was $151.9 million as of December 31, 2025.

      Adjusted Results

      Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):


      For the Three Months
      Ended December 31,


      For the Year Ended
      December 31,


      2025


      2024


      2025


      2024

      Adjusted cost of revenue

      $   371,183


      $    569,578


      $   1,473,115


      $   2,182,806

      Adjusted selling, general and administrative expenses

      $     59,743


      $      54,352


      $      251,959


      $      211,475

      Adjusted EBITDA

      $     37,793


      $      22,612


      $      151,155


      $      160,460

      Adjusted EBITDA margin

      8.1 %


      3.5 %


      8.1 %


      6.3 %

      Adjusted income (loss) attributable to common shareholders

      $       8,376


      $      (2,526)


      $        10,440


      $        47,406

      Adjusted income (loss) per share attributable to common shareholders:








      Basic

      $         0.08


      $        (0.02)


      $           0.09


      $           0.41

      Business Outlook        

      The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, gain (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.

      Full Year 2026 Guidance

      Incorporating its year-to-date performance, the Company now expects revenue for the full year ending December 31, 2026 to be in the range of approximately $2.4 billion to $2.6 billion and Adjusted EBITDA to be in the range of approximately $110 million to $140 million, respectively. The Company continues to experience strong customer retention and late-stage pipeline activity.

      Additional Outlook Information

      The Company expects to deploy approximately $25 million to $35 million in cash for capitalized software development during 2026.

      This "Business Outlook" section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").

      Web and Conference Call Information

      Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this evening, February 24, 2026, at 5:00 p.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com. To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the "Evolent Health call." Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the Company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.

      About Evolent

      Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.

      Contacts:

      [email protected]

      Definitions

      Revenue Agreements

      Evolent reports the number of new revenue agreements signed for Performance Suite, Specialty Technology and Services Suite, Administrative Services and Case-based products. A new revenue agreement includes incremental revenue to the Company reflecting contracts for services to both new partner entities, corporations or health plans as well as additional sales to existing partners. New revenue agreements may include incremental services, geographic, or line of business expansions or a combination thereof. The conversion of Specialty Technology and Services Suite contracts to Performance Suite are also included in this definition. The Company does not count renewals for existing scope, growth of membership within an existing contract scope or transaction-related purchase agreements, if applicable, in this metric. 

      Lives on Platform and Per Member Per Month ("PMPM") Fee

      Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostic specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category.

      Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.

      Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where partners cross between multiple solutions, we only capture members from the solution with the maximum number of members.

      Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

      Medical Expense Ratio

      Medical Expense Ratio ("MER") is a key performance indicator used by management for purposes of monitoring operating performance and is calculated as total claims incurred divided by GAAP revenue related to our Performance Suite. Management believes MER is useful to investors because it provides insight into the efficiency with which medical costs are managed relative to revenue and helps identify trends in the underlying performance. For periods prior to the consummation of the sale of Evolent Care Partners, we present MER excluding revenues from Evolent Care Partners.

      EVOLENT HEALTH, INC.
      CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
       
      ( in thousands, except per share data)

       


      For the Three Months
      Ended December 31,


      For the Year Ended
      December 31,


      2025


      2024


      2025


      2024

      Revenue

      $     468,719


      $   646,542


      $ 1,876,229


      $   2,554,741

      Expenses








      Cost of revenue

      371,466


      570,831


      1,476,346


      2,187,388

      Selling, general and administrative expenses

      72,656


      47,701


      303,866


      263,050

      Depreciation and amortization expenses

      45,037


      29,296


      115,851


      118,370

      Loss on lease termination

      —


      18,922


      676


      18,922

      Gain on disposal of non-strategic assets

      (14,867)


      —


      (14,867)


      —

      Right-of-use assets impairment

      —


      2,588


      —


      2,588

      Goodwill impairment

      398,000


      —


      398,000


      —

      Change in fair value of contingent consideration

      4,658


      (4,200)


      6,495


      4,908

      Total operating expenses

      876,950


      665,138


      2,286,367


      2,595,226

      Operating income (loss)

      (408,231)


      (18,596)


      (410,138)


      (40,485)

      Interest income

      868


      830


      4,190


      5,544

      Interest expense

      (19,010)


      (6,720)


      (57,471)


      (24,722)

      Gain (loss) from equity method investees

      31


      182


      365


      (3,441)

      Loss on extinguishment of debt, net

      (3,914)


      —


      (3,483)


      —

      Loss on option exercise

      —


      —


      (52,544)


      —

      Extinguishment of Series A Preferred Stock and other refinancing fees

      —


      —


      (15,000)


      —

      Change in tax receivables agreement liability

      (804)


      —


      (804)


      (173)

      Other expense, net

      252


      381


      249


      241

      Loss before income taxes

      (430,808)


      (23,923)


      (534,636)


      (63,036)

      Benefit from income taxes

      (1,677)


      (1,121)


      (126)


      (1,413)

      Loss before preferred dividends and accretion of Series A Preferred Stock including excise tax

      (429,131)


      (22,802)


      (534,510)


      (61,623)

      Dividends and accretion of Series A Preferred Stock including excise tax

      —


      (7,813)


      (44,891)


      (31,831)

      Net loss attributable to common shareholders of Evolent Health, Inc.

      $    (429,131)


      $   (30,615)


      $ (579,401)


      $      (93,454)









      Loss per common share








      Basic and diluted

      $         (3.84)


      $       (0.27)


      $      (5.07)


      $         (0.81)









      Weighted-average common shares outstanding








      Basic and diluted

      111,612


      115,032


      114,208


      114,682









      Comprehensive loss








      Net loss attributable to common shareholders of Evolent Health, Inc.

      $    (429,131)


      $   (30,615)


      $ (579,401)


      $      (93,454)

      Other comprehensive loss, net of taxes, related to:








      Foreign currency translation adjustment

      (248)


      (386)


      (871)


      (496)

      Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.

      $    (429,379)


      $   (31,001)


      $ (580,272)


      $      (93,950)

      EVOLENT HEALTH, INC.

      CONSOLIDATED BALANCE SHEETS

      (in thousands, except share data)

       


      December 31,


      2025


      2024





      ASSETS




      Current assets:




      Cash and cash equivalents

      $              151,856


      $             104,203

      Restricted cash

      26,134


      59,295

      Accounts receivable, net

      309,861


      414,681

      Prepaid expenses and other current assets

      18,521


      28,938

      Total current assets

      506,372


      607,117

      Restricted cash

      2,706


      14,998

      Investments and equity method investees

      8,966


      8,588

      Property and equipment, net

      80,785


      73,151

      Right-of-use assets - operating

      4,373


      6,134

      Prepaid expenses and other noncurrent assets

      3,078


      3,569

      Contract cost assets

      13,537


      13,378

      Intangible assets, net

      584,937


      680,156

      Goodwill

      694,482


      1,137,320

      Total assets

      $           1,899,236


      $          2,544,411

      LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY




      Liabilities




      Current liabilities:




      Accounts payable

      $                59,776


      $               96,025

      Accrued liabilities

      65,755


      66,361

      Operating lease liability - current

      15,343


      26,717

      Accrued compensation and employee benefits

      50,987


      33,719

      Deferred revenue

      1,203


      2,507

      Short-term debt, net

      —


      171,467

      Reserve for claims and performance - based arrangements

      192,196


      318,705

      Total current liabilities

      385,260


      715,501

      Long-term debt, net

      970,537


      490,520

      Other long-term liabilities

      8,012


      2,984

      Tax receivables agreement liability

      108,909


      108,105

      Operating lease liabilities - noncurrent

      3,818


      24,969

      Deferred tax liabilities, net

      7,506


      10,900

      Total liabilities

      1,484,042


      1,352,979

      Commitments and Contingencies




      Mezzanine Equity




      Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 0 and 175,000 issued, respectively

      —


      190,173

      Shareholders' Equity




      Class A common stock - $0.01 par value; 750,000,000 shares authorized; 117,603,806 and 116,575,773 shares issued, respectively

      1,176


      1,166

      Additional paid-in-capital

      1,793,398


      1,803,786

      Accumulated other comprehensive loss

      (2,624)


      (1,753)

      Retained earnings (accumulated deficit)

      (1,315,327)


      (780,817)

      Treasury stock, at cost; 5,971,712 and 1,537,582 shares issued, respectively

      (61,429)


      (21,123)

      Total shareholders' equity

      415,194


      1,001,259

      Total liabilities, mezzanine equity and shareholders' equity

      $           1,899,236


      $          2,544,411

      EVOLENT HEALTH, INC.

      CONSOLIDATED STATEMENTS OF CASH FLOWS

       (in thousands)

       


      For the Year Ended December 31,


      2025


      2024

      Cash Flows Provided by Operating Activities




      Loss before preferred dividends and accretion of Series A Preferred Stock including excise tax

      $           (534,510)


      $             (61,623)

      Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities:




      Change in fair value of contingent consideration

      6,495


      4,908

      Gain on disposal of non-strategic assets

      (14,867)


      —

      Loss (gain) from equity method investees

      (365)


      3,441

      Extinguishment of Series A Preferred Stock and other refinancing fees

      15,000


      —

      Loss on option exercise

      52,544


      —

      Depreciation and amortization expenses

      115,851


      118,370

      Stock-based compensation expense

      39,739


      39,746

      Deferred tax benefit

      (2,982)


      (2,989)

      Amortization of contract cost assets

      6,794


      4,798

      Amortization of deferred financing costs

      7,804


      3,547

      Goodwill impairment

      398,000


      —

      Loss on extinguishment/repayment of debt, net

      3,483


      —

      Right-of-use asset impairment

      —


      2,588

      Loss on lease termination

      676


      18,922

      Change in tax receivables agreement liability

      804


      173

      Right-of-use operating assets

      1,761


      3,261

      Other current operating cash inflows (outflows), net

      —


      180

      Changes in assets and liabilities, net of acquisitions:




      Accounts receivable, net and contract assets

      73,703


      32,062

      Prepaid expenses and other current and non-current assets

      4,988


      4,510

      Contract cost assets

      (6,953)


      (6,056)

      Accounts payable

      6,639


      4,248

      Accrued liabilities

      2,957


      (24,198)

      Operating lease liabilities

      (33,201)


      (14,983)

      Accrued compensation and employee benefits

      17,268


      (22,675)

      Deferred revenue

      (1,304)


      (3,469)

      Reserve for claims and performance-based arrangements

      (126,509)


      (85,343)

      Other long-term liabilities

      5,028


      (653)

      Net cash and restricted cash provided by operating activities

      38,843


      18,765

      Cash Flows Used In Investing Activities




      Cash paid for asset acquisitions and business combinations

      (57,443)


      (30,725)

      Disposal of non-strategic assets and divestiture of discontinued operations, net

      91,312


      —

      Return of equity method investments

      986


      7

      Purchases of investments and contributions to equity method investees

      (1,000)


      (7,321)

      Investments in internal-use software and purchases of property and equipment

      (34,088)


      (24,893)

      Net cash and restricted cash used in investing activities

      (233)


      (62,932)

      Cash Flows Used In Financing Activities




      Changes in working capital balances related to claims processing

      (42,888)


      43,537

      Payment of contingent consideration

      (1,750)


      (70,355)

      Proceeds from stock option exercises

      —


      3,461

      Proceeds from issuance of long-term debt, net of offering costs

      408,047


      58,576

      Repayment of long-term debt

      (342,984)


      —

      Repurchase of common stock

      (39,996)


      —

      Payment of preferred dividends

      (11,127)


      (20,085)

      Taxes withheld and paid for vesting of equity awards

      (5,226)


      (15,699)

      Net cash and restricted cash used in financing activities

      (35,924)


      (565)

      Effect of exchange rate on cash and cash equivalents and restricted cash

      (486)


      (229)

      Net increase (decrease) in cash and cash equivalents and restricted cash

      2,200


      (44,961)

      Cash and cash equivalents and restricted cash as of beginning-of-period

      178,496


      223,457

      Cash and cash equivalents and restricted cash as of end-of-period

      $            180,696


      $            178,496

      Non-GAAP Financial Measures

      The Company views the following activities as integral to understanding its non-GAAP financial measures:

      • Repositioning costs include severance, termination benefits and related payroll taxes of $1.8 million, dedicated employee costs of $1.2 million, third-party professional services of $4.1 million and office space consolidation costs of $3.5 million for the year ended December 31, 2024. Repositioning costs are not part of Evolent's normal course of business and are incurred when there is a business reason to enact a repositioning plan. Adjusting for these costs gives a better view of Evolent's normal operating costs. We only adjust costs that (i) are included within selling, general and administrative expenses on the consolidated statement of operations and comprehensive income (loss), (ii) meet the criteria outlined within the respective repositioning plan, and (iii) do not relate to normal business operations or ongoing activities. Our 2023 Repositioning Plan concluded in the second quarter of 2024.
        • Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent's integrated technology platform and costs related to the consolidation of internal operations, strategies, processes and platforms. Dedicated employee costs are limited to employees that will have no role in ongoing operations and have no planned role at Evolent once the repositioning activities are completed.
        • Professional services costs primarily relate to services provided by a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.
        • Office space consolidation costs include early termination penalties and associated expenses.
      • Transaction-related costs include but are not limited to integration consultants, investor outreach services, external valuation and accounting advisory services, legal fees, transaction bonuses paid to certain employees and other transaction related costs. We adjust these costs because transaction-related costs are expensed when incurred and are not indicative of Evolent's normal operating costs.
      • Purchase accounting adjustments include amortization expense on intangible assets such as corporate trade names, customer, relationships, provider network contracts and existing technology related to acquisitions and business combinations. We believe it is important for the reader to understand that revenue generated from acquisitions is included within revenue in calculating adjusted income to common shareholders however amortization expense from acquired intangible assets is excluded in determining adjusted income to common shareholders because it does not directly relate to the services performed for the Company's customers.

      In addition to disclosing financial results that are determined in accordance with GAAP, we present Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Income (Loss) Attributable to Common Shareholders, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.

      Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses calculated in accordance with GAAP, respectively, adjusted to exclude the impact of stock-based compensation expenses, severance costs, transaction-related costs and repositioning costs. Management believes Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are useful to investors, because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.

      Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, benefit from income taxes, depreciation and amortization expenses, change in the tax receivable agreement liability, extinguishment of Series A Preferred Stock and other refinancing fees, gain (loss) from equity method investees, loss on extinguishment/repayment of debt, loss on option exercise, change in fair value of contingent consideration, other income (expense), net, gain on disposal of non-strategic assets, goodwill impairment, right-of-use assets impairment, loss on lease termination, repositioning costs, stock-based compensation expense, severance costs, dividends and accretion of Series A Preferred Stock including excise tax and transaction-related costs.

      Management believes that Adjusted EBITDA is useful to investors because it allows investors to evaluate the Company's performance using tools that management uses to evaluate past performance and prospects for future performance. Management also uses Adjusted EBITDA as a supplemental performance measure because the removal of adjustments to net loss attributable to common shareholders of Evolent Health, Inc. allows us to focus on operational performance.

      Adjusted EBITDA Margin is defined Adjusted EBITDA divided by Revenue. Management believes that this measure is useful to investors because it allows further insight into the period over period operational performance. Management also uses Adjusted EBITDA Margin as a supplemental performance measure because it allows the investor to understand operational performance compared to revenues over time.

      Adjusted Income (Loss) Attributable to Common Shareholders is defined as net loss attributable to common shareholders of Evolent Health, Inc. adjusted to exclude gain (loss) from equity method investees, other income (expense), net, benefit from income taxes, change in fair value of contingent consideration, extinguishment of Series A Preferred Stock and other refinancing fees, loss on option exercise, loss on extinguishment/repayment of debt, change in tax receivable agreement liability, purchase accounting adjustments, gain on disposal of non-strategic assets, goodwill impairment, right-of-use asset impairments, loss on lease termination, repositioning costs, stock-based compensation expense, severance costs, transaction-related costs and the tax impact of non-GAAP adjustments.

      Adjusted Income (Loss) per Share Attributable to Common Shareholders is defined as Adjusted Income (Loss) Attributable to Common Shareholders divided by Weighted-Average Common Shares, and reflects the adjustments made in those non-GAAP measures.

      Management believes that Adjusted Income (Loss) Attributable to Common Shareholders and Adjusted Income (Loss) per Share Attributable to Common Shareholders are useful to investors because they provide a measure of the Company's net profitability on a more comparable basis to historical periods and provide a more meaningful basis for forecasting future performance.

      These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.

      Evolent Health, Inc.

      Reconciliation of Adjusted Results of Operations

      (in thousands, unaudited)

       

      Reconciliation of Adjusted Cost of Revenue to

      Cost of Revenue


      For the Three Months Ended December 31,


      For the Year Ended December 31,


      2025


      2024


      2025


      2024

      Cost of revenue

      $    371,466


      $    570,831


      $ 1,476,346


      $ 2,187,388

      Less:








      Stock-based compensation

      283


      1,253


      3,231


      4,582

      Adjusted cost of revenue

      $    371,183


      $    569,578


      $ 1,473,115


      $ 2,182,806

















      Reconciliation of Adjusted Selling, General and Administrative Expenses to

      Selling, General and Administrative Expenses


      For the Three Months Ended December 31,


      For the Year Ended December 31,


      2025


      2024


      2025


      2024

      Selling, general and administrative expenses

      $      72,656


      $      47,701


      $    303,866


      $    263,050

      Less:








      Stock-based compensation

      2,113


      (7,368)


      36,508


      35,164

      Severance costs

      6,802


      17


      10,147


      2,877

      Transaction-related costs

      3,998


      700


      5,252


      2,934

      Repositioning costs

      —


      —


      —


      10,600

      Adjusted selling, general and administrative expenses

      $      59,743


      $      54,352


      $    251,959


      $    211,475

      Evolent Health, Inc.

      Reconciliation of Medical Expense Ratio

      (in thousands)

       


      For the Three
      Months Ended
      December 31, 2025


      For the Year Ended
      December 31, 2025

      Revenue




      Performance Suite

      $               269,463


      $            1,127,336

      Specialty Technology and Services Suite

      95,743


      353,228

      Administrative Services

      55,801


      226,683

      Cases

      47,712


      168,982

      Total revenue

      468,719


      1,876,229

      Less:




      Revenue from ECP

      13,030


      107,848

      Performance Suite revenue less revenue from Evolent Care Partners

      256,433


      1,019,488





      Total claims incurred

      243,157


      907,304





      Medical expense ratio

      90.2 %


      80.5 %

      Medical expense ratio excluding Evolent Care Partners

      94.8 %


      89.0 %

      Evolent Health, Inc.

      Reconciliation of Adjusted EBITDA to Net Income (Loss)

      Attributable to Common Shareholders of Evolent Health, Inc.

      (in thousands)

      (unaudited)

       


      For the Three Months
      Ended December 31,


      For the Year Ended
      December 31,


      2025


      2024


      2025


      2024

      Net loss attributable to common shareholders of Evolent Health, Inc.

      $  (429,131)


      $    (30,615)


      $(579,401)


      $(93,454)

      Net loss margin

      (91.6) %


      (4.7) %


      (30.9) %


      (3.7) %









      Less:








      Interest income

      868


      830


      4,190


      5,544

      Interest expense

      (19,010)


      (6,720)


      (57,471)


      (24,722)

      Benefit from income taxes

      1,677


      1,121


      126


      1,413

      Depreciation and amortization expenses

      (45,037)


      (29,296)


      (115,851)


      (118,370)

      Change in tax receivable agreement liability

      (804)


      —


      (804)


      (173)

      Extinguishment of Series A Preferred Stock and other refinancing fees

      —


      —


      (15,000)


      —

      Gain (loss) from equity method investees

      31


      182


      365


      (3,441)

      Loss on extinguishment/repayment of debt

      (3,914)


      —


      (3,483)


      —

      Loss on option exercise

      —


      —


      (52,544)


      —

      Change in fair value of contingent consideration

      (4,658)


      4,200


      (6,495)


      (4,908)

      Other income (expense), net

      252


      381


      249


      241

      Gain on disposal of non-strategic assets

      14,867


      —


      14,867


      —

      Goodwill impairment

      (398,000)


      —


      (398,000)


      —

      Right-of-use assets impairment

      —


      (2,588)


      —


      (2,588)

      Loss on lease termination

      —


      (18,922)


      (676)


      (18,922)

      Repositioning costs

      —


      —


      —


      (10,600)

      Stock-based compensation expense

      (2,396)


      6,115


      (39,739)


      (39,746)

      Severance costs

      (6,802)


      (17)


      (10,147)


      (2,877)

      Dividends and accretion of Series A Preferred Stock including excise tax

      —


      (7,813)


      (44,891)


      (31,831)

      Transaction-related costs

      (3,998)


      (700)


      (5,252)


      (2,934)

      Adjusted EBITDA

      $   37,793


      $     22,612


      $ 151,155


      $ 160,460









      Adjusted EBITDA margin

      8.1 %


      3.5 %


      8.1 %


      6.3 %

       Evolent Health, Inc.

      Reconciliation of Adjusted Income (Loss) Attributable to Common Shareholders to

      Net Loss Attributable to Common Shareholders

      (in thousands, except per share data)

      (unaudited)

       


      For the Three Months
      Ended December 31,


      For the Year Ended
      December 31,


      2025


      2024


      2025


      2024

      Net loss attributable to common shareholders of Evolent Health, Inc.

      $    (429,131)


      $      (30,615)


      $   (579,401)


      $     (93,454)

      Less:








      Gain (loss) from equity method investees

      31


      182


      365


      (3,441)

      Other income (expense), net

      252


      381


      249


      241

      Benefit from income taxes

      1,677


      1,121


      126


      1,413

      Change in fair value of contingent consideration

      (4,658)


      4,200


      (6,495)


      (4,908)

      Extinguishment of Series A Preferred Stock and other refinancing fees

      —


      —


      (15,000)


      —

      Loss on option exercise

      —


      —


      (52,544)


      —

      Loss on extinguishment/repayment of debt

      (3,914)


      —


      (3,483)


      —

      Change in tax receivable agreement liability

      (804)


      —


      (804)


      (173)

      Purchase accounting adjustments

      (35,990)


      (17,189)


      (76,083)


      (68,926)

      Gain on disposal of non-strategic assets

      14,867


      —


      14,867


      —

      Goodwill impairment

      (398,000)


      —


      (398,000)


      —

      Right-of-use asset impairment

      —


      (2,588)


      —


      (2,588)

      Loss on lease termination

      —


      (18,922)


      (676)


      (18,922)

      Repositioning costs

      —


      —


      —


      (10,600)

      Stock-based compensation expense

      (2,396)


      6,115


      (39,739)


      (39,746)

      Severance costs

      (6,802)


      (17)


      (10,147)


      (2,877)

      Transaction-related costs

      (3,998)


      (700)


      (5,252)


      (2,934)

      Tax impact (1)

      2,228


      (672)


      2,775


      12,601

      Adjusted income (loss) attributable to common shareholders

      $         8,376


      $        (2,526)


      $      10,440


      $      47,406









      Loss per share attributable to common shareholders








      Basic

      $         (3.84)


      $         (0.27)


      $        (5.07)


      $        (0.81)









      Adjusted income (loss) per share attributable to common shareholders








      Basic

      $           0.08


      $         (0.02)


      $          0.09


      $          0.41









      Weighted-average common shares








      Basic

      111,612


      115,032


      114,208


      114,682

      ————————

      (1)  Non-GAAP financial information for the periods shown are adjusted for an assumed provision for income taxes based on our statutory federal tax rate of 21%. Due to the differences in the tax treatment of items excluded from non-GAAP earnings, our estimated tax rate on non-GAAP income may differ from our GAAP tax rate.

      FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE

      Certain statements made in this report and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to weather current dynamics, continue to expand our footprint, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.

      These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements. Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:

      • the significant portion of revenue we derive from our largest partners, and the potential loss, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;
      • the increasing number of risk-sharing arrangements we enter into with our partners;
      • the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes;
      • our ability to accurately predict our exposure under performance-based contracts;
      • failure by our customers to provide us with accurate and timely information;
      • our ability to recover the upfront costs in our partner relationships and develop our partner relationships over time;
      • our ability to attract new partners and successfully capture new opportunities;
      • our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners' needs;
      • our ability to maintain and enhance our reputation and brand recognition;
      • our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;
      • risks related to completed and future acquisitions, investments, alliances and joint ventures, which could divert management resources, result in unanticipated costs or dilute our stockholders;
      • our ability to effectively manage our growth and maintain an efficient cost structure;
      • risks related to managing our offshore operations and cost reduction goals;
      • our ability to estimate the size of our target markets for our services;
      • consolidation in the health care industry;
      • competition which could limit our ability to maintain or expand market share within our industry;
      • risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act;
      • evolution of the healthcare regulatory and political framework;
      • restrictions on the manner in which we access personal data and penalties as a result of privacy and data protection laws;
      • data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;
      • liabilities and reputational risks related to our ability to safeguard the security and privacy of confidential data;
      • our ability to obtain, maintain and enforce intellectual property rights and protect our trademarks and trade names, including from third parties alleging that we are infringing or violating their intellectual property rights;
      • our ability to protect the confidentiality of our trade secrets;
      • risks associated with our use of artificial intelligence ("AI") and machine learning models;
      • our use of "open-source" software;
      • our reliance on third parties and licensed technologies;
      • restrictions on our ability to use, disclose, de-identify or license data and to integrate third-party technologies;
      • our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners and operating our business;
      • our ability to achieve profitability in the future;
      • the impact of additional goodwill and intangible asset impairments on our results of operations;
      • our obligations to make material payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;
      • our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;
      • our ability to utilize benefits under the tax receivables agreement described herein;
      • the terms of agreements between us and certain of our pre-IPO investors may contain different terms than comparable agreement we may enter into with unaffiliated third parties;
      • our inability to obtain financing may result in a reduction in the ownership of our stockholders;
      • the conditional conversion features, and changes in accounting treatment of the 2029 Notes and the 2031 Notes, which, if triggered, may adversely affect our financial condition and operating results;
      • our ability to raise funds necessary to settle conversions of our notes in cash, to repurchase our notes for cash upon a fundamental change or to pay the redemption price for any notes we redeem;
      • interest rate risk and other restrictive covenants under our First Lien Credit Agreement and the second lien credit agreement, by and among the Company, Evolent Health LLC, as borrower (the "Borrower"), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent;
      • our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing on favorable terms or at all;
      • interference with our ability to access the first and second lien credit facilities under our Credit Agreements;
      • the potential volatility of our Class A common stock price;
      • provisions in our certificate of incorporation and by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;
      • provisions in our certificate of incorporation which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees;
      • our intention not to pay cash dividends on our Class A common stock;
      • the impact of litigation proceedings, government inquiries, reviews, audits or investigations;
      • public health emergencies, epidemics, pandemics or contagious diseases;
      • the cost of compliance with sustainability or other environmental, social responsibility or governance law and regulations;
      • the impact of increasing inflationary pressures and rising consumer costs on our business; and
      • our ability to utilize our net operating loss carry forwards and certain other tax attributes may be limited.

      The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Our periodic reports and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.

      Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this release.

      SOURCE Evolent Health, Inc.

      Modal title

      Also from this source

      Evolent Announces Third Quarter 2026 Results

      Evolent Announces Third Quarter 2026 Results

      Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex...

      Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026

      Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026

      Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.